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Natriuretic Peptides
Lori B. Daniels, MD, Alan S. Maisel, MD, FACC
San Diego, California
Natriuretic peptides (NPs) are released from the heart in response to pressure and volume overload. B-type natri-
uretic peptide (BNP) and N-terminal-proBNP have become important diagnostic tools for assessing patients who
present acutely with dyspnea. The NP level reflects a compilation of systolic and diastolic function as well as
right ventricular and valvular function. Studies suggest that using NPs in the emergency department can reduce
the consumption of hospital resources and can lower costs by either eliminating the need for other, more expen-
sive tests or by establishing an alternative diagnosis that does not require hospital stay. Caveats such as body
mass index and renal function must be taken into account when analyzing NP levels. Natriuretic peptide levels
have important prognostic value in multiple clinical settings, including in patients with stable coronary artery
disease and with acute coronary syndromes. In patients with decompensated heart failure due to volume over-
load, a treatment-induced drop in wedge pressure is often accompanied by a rapid drop in NP levels. Knowing a
patient’s NP levels might thus assist with hemodynamic assessment and subsequent treatment titration. Moni-
toring NP levels in the outpatient setting might also improve patient care and outcomes. (J Am Coll Cardiol
2007;50:2357–68) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.09.021t
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fhe Basics
hysiology of natriuretic peptides (NPs). There are 3
ajor NPs, atrial natriuretic peptide (ANP), B-type natri-
retic peptide (BNP), and C-type NP, all of which share a
ommon 17-amino-acid ring structure and have actions that
re targeted at protecting the cardiovascular system from the
ffects of volume overload. The ANP and BNP are released
rimarily from the heart but circulate as hormones to act in
arious tissues in the body and induce vasodilation, natri-
resis, and diuresis (1). Although ANP is preferentially
ynthesized and secreted from the atria and BNP from the
entricles, both can be synthesized in either chamber under
athologic conditions (2). Unlike ANP, which is stored in
ranules and thus released with even minor triggers such as
xercise, BNP has minimal storage in granules; rather, it is
ynthesized and secreted in bursts (3). C-type NP, derived
rimarily from endothelial cells, is also synthesized in
yocardial tissue and might protect against remodeling
ffects in the post-myocardial infarction (MI) setting (4).
In the setting of volume expansion or pressure overload,
he resulting wall stress initiates synthesis of pre–proBNP in
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007, accepted September 26, 2007.he ventricular myocardium. Subsequently, the peptide is
leaved first to proBNP1-108, then to the biologically active
NP1-32 and the inactive amino-terminal fragment
NTproBNP). The release of BNP results in improved
yocardial relaxation and serves an important regulatory
ole in response to acute increases in ventricular volume by
pposing the vasoconstriction, sodium retention, and anti-
iuretic effects of the activated renin-angiotensin-
ldosterone system (5). The biological actions of NPs are
ediated through membrane-bound natriuretic peptide re-
eptors (NPRs) that are linked to a cyclic guanosine
onophosphate-dependent signaling cascade, including
PR-A, which preferentially binds ANP and BNP, and
PR-B, which preferentially binds C-type NP. Clearance
f NPs from the blood is mediated by NPR-C. In addition,
NP is degraded by neutral endopeptidase, which opens the
ing structure and inactivates the peptide. Direct renal
ltration and passive excretion might be responsible for
ome BNP clearance as well.
irculating forms of NPs in heart failure (HF). Al-
hough blood levels of NPs rise to very high levels in
he setting of acute HF, recent studies support the
otion that HF patients actually manifest a state of BNP
nsufficiency, due to both a deficiency of biologically
ctive BNP1-32 and resistance to its effects (6). Evidence
or a state of deficiency comes from molecular analysis of
NP in subjects with acute HF, which reveals 2 distinct
irculating forms of BNP: a high-molecular weight form,
hought to be proBNP1-108, and a low-molecular weight
orm, the 32-amino acid active BNP1-32 (7). Instead of
ecognizing BNP1-32 or NTproBNP alone, recent studies
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assays also recognize the high-
molecular weight proBNP1-108,
which comprises a significant per-
centage of immunoreactive BNP
in HF patients yet seems to have
less biologic activity than BNP1-32,
thus explaining the paradox of
HF as an NP-deficient state de-
spite high levels of these biomar-
kers (8,9). Abnormal processing
of proBNP into less active forms
might also factor into the state of
relative BNP insufficiency (10).
In addition, HF patients seem
to suffer some degree of BNP
resistance. Animal studies have
implicated an up-regulation of
phosphodiesterase in HF, caus-
ing impaired cyclic-GMP activ-
ity despite high stimulation of
the NPRs by NPs (11). Taken
together, these studies help ex-
plain the paradox of high mea-
surable BNP and NTproBNP
levels in HF patients who none-
theless suffer physiologically
from a state of BNP deficiency
and its attendant fluid and salt
retention.
NTproBNP versus BNP. Per-
ormance characteristics for BNP and NTproBNP are
imilar in many clinical scenarios. In general, BNP and
TproBNP levels are reasonably correlated, and either can
e used in patient care, although clinicians must understand
heir differences and that absolute levels are not inter-
hangeable (Table 1). The choice of which NP to use often
omes down to an institutional decision.
The BNP has a half-life of approximately 20 min and is
uickly cleared via several mechanisms as described in the
NP Versus NTproBNP
Table 1 BNP Versus NTproBNP
BNP NTproBNP
Amino acids 32 76
Molecular weight (kd) 3.5 8.5
Half-life (min) 22 60–120
Clearance
Primary mechanism Neutral endopeptidase Renal
Clearance receptor NPR-C Renal
Hemodialysis No No
Point-of-care Yes Pending
Correlation with GFR Moderate Strong
Biologically active Yes No
Clinical range (pg/ml) 0–5,000 0–35,000
Abbreviations
and Acronyms
AF  atrial fibrillation
ANP  atrial natriuretic
peptide
AUC  area under the
receiver-operating
characteristic curve
BNP  B-type natriuretic
peptide
CAD  coronary artery
disease
CHF  congestive heart
failure
ED  emergency
department
GFR  glomerular filtration
rate
HF  heart failure
LV  left
ventricle/ventricular
MI  myocardial infarction
NP  natriuretic peptide
NPR  natriuretic peptide
receptor
NTproBNP  amino-terminal
fragment of B-type
natriuretic peptide
NYHA  New York Heart
Associationr
NP  B-type natriuretic peptide; GFR  glomerular filtration rate; NPR-C  natriuretic peptide
eceptor-C; NTproBNP  amino-terminal fragment of B-type natriuretic peptide.revious text. The NTproBNP, in contrast, has a longer
alf-life of approximately 1 to 2 h, leading to higher
irculating levels and slower fluctuations compared with
NP, despite the 1:1 secretion. Both peptides are influenced
y renal function, but the effect seems to be greater for
TproBNP (12); however, the clinical implications of this
eem to be modest, especially in patients with HF.
hat is a “normal” value? The definition of a “normal”
P level depends upon the clinical feature being detected
i.e., severe, symptomatic left ventricular [LV] dysfunction
ersus subclinical disease) and the prevalence of that condi-
ion in the population being tested, because different thresh-
lds will be needed in different clinical settings. In addition,
he specific assay used can affect NP levels, particularly when
creening the general population, in which NP levels will
end to fall toward the lower end of the spectrum.
Natriuretic peptide levels are clearly age- and gender-
pecific. Two studies looked at BNP levels in normal
ubjects without cardiovascular disease or ventricular (sys-
olic or diastolic) dysfunction and found increased levels
ith age and in women (13,14). Therefore, “normal” values
ary.
As a general guideline, in young, healthy adults, 90% will
ave BNP 25 pg/ml and NTproBNP 70 pg/ml (15).
or acutely dyspneic patients, some have suggested cutoffs
f BNP 100 pg/ml and NTproBNP 300 pg/ml to rule
ut HF (Fig. 1) (16,17).
iagnosis With NPs
Ps in dyspnea. The BNP and NTproBNP have become
mportant diagnostic tools for assessing patients who
resent acutely with dyspnea. In the Breathing Not Properly
ultinational Study, BNP levels measured on arrival in
,586 emergency department (ED) patients presenting with
cute shortness of breath had higher diagnostic accuracy
hat did the ED physician in diagnosing HF, with an area
nder the receiver-operating characteristic curve (AUC) of
.91 (16). A BNP cut-point of 100 pg/ml was 90% sensitive
nd 76% specific for diagnosing HF as the cause of dyspnea.
The PRIDE (ProBNP Investigation of Dyspnea in the
D) study was a similar study performed with NTproBNP,
easured in 600 patients who presented to a single ED with
yspnea. In this study, NTproBNP was sensitive and
pecific for the diagnosis of congestive heart failure (CHF)
AUC  0.94). Patients with acute HF had a median
TproBNP over 4,000 pg/ml, compared with 130 pg/ml in
hose without acute HF. An NTproBNP cut-point of 300
g/ml was proposed to “rule-out” a diagnosis of HF,
hereas higher age-dependent cut-points were suggested to
rule-in” HF (AUC  0.94) (17).
The cost-effectiveness of using BNP to aid in the emer-
ency diagnosis of HF was shown in the BASEL (BNP for
cute Shortness of breath EvaLuation) study, in which 452
atients presenting to the ED with acute dyspnea were
andomized to undergo either a single measurement of BNP
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NP levels by ED physicians was associated with a 10%
ecrease in the rate of hospital admission and a 3-day
ecrease in the median length of stay, at a total cost savings
f approximately $1,800/patient without increased mortality
r repeat hospital stays. Similar improvements in diagnosis
nd cost savings were seen in the IMPROVE-CHF (Im-
roved Management of Patients With Congestive Heart
ailure) study of NTproBNP use in the ED (19).
IASTOLIC HF. The BNP levels are also useful in establish-
ng a diagnosis of diastolic dysfunction in acute HF patients
20). As diastolic dysfunction increases in severity as as-
essed by Doppler filling patterns of mitral inflow and
ulmonary venous flow, BNP levels rise accordingly (21) as
reflection of LV end-diastolic wall stress (22).
Ps in other clinical scenarios. Several clinical scenarios
xist that can cause NP levels to rise, apart from the typical
cute HF setting. Acknowledging these other etiologies for
levated NP levels might help clarify what might otherwise
eem to be a discordant clinical picture (Table 2).
REVIOUS HF. The Breathing Not Properly trial demon-
trated that NP levels can be elevated in patients with a
istory of HF who present with dyspnea but without an
cute HF exacerbation. In this setting, patients’ BNP levels
end to be intermediate, in between those without HF and
hose with an acute HF diagnosis (16).
CUTE CORONARY SYNDROME. Acute coronary syndrome
s associated with a rise in NP levels even in the absence of
oncomitant HF. The degree of elevation might reflect the
Figure 1 BNP Levels by ACC/AHA Heart Failure Stages
B-type natriuretic peptide (BNP) rises with age over the course of a lifetime but
generally stays under 20 pg/ml in the absence of left ventricular dysfunction or
structural heart disease. B-type natriuretic peptide 100 pg/ml is the cutoff
for diagnosing congestive heart failure in symptomatic patients. Stage A  risk
factors; Stage B  asymptomatic structural heart disease; Stage C  symp-
tomatic heart failure; Stage D  refractory heart failure. ACC  American Col-
lege of Cardiology; AHA  American Heart Association.everity of LV dysfunction (23). Some have suggested using
fP levels as a guide to institute more aggressive treatments
imed at reducing ventricular wall stress (24).
ULMONARY DISEASE. Differentiating between patients
ith a pulmonary etiology for their dyspnea and a cardiac
tiology can be clinically challenging at times, and the fact
hat NP levels can be elevated in both settings might
onfound the picture. However, although patients with
ulmonary disease can have elevated NP levels, their eleva-
ions often fall within the gray zone and are not usually as
igh as in patients with CHF (25). Natriuretic peptide
evels can still be useful in diagnosing HF in patients with a
istory of lung disease, such as chronic obstructive pulmo-
ary disease or asthma, because levels will often be higher in
atients with both HF and pulmonary disease than in
ulmonary disease alone (BNP levels 587 vs. 109 pg/ml,
espectively, in the 417 patients from the Breathing Not
roperly study with a history of pulmonary disease [asthma
r chronic obstructive pulmonary disease] plus a new diag-
osis of HF versus those with a history of pulmonary disease
ithout HF) (26).
Elevated NP levels can also be seen in the setting of an
cute, hemodynamically significant pulmonary embolism,
ikely reflecting right heart strain (27). In fact, right heart
ysfunction due to severe lung disease from a variety of
tiologies can cause elevated NP levels. The mechanism is
ikely due to release of peptide from the right ventricular
yocardium (28), although decreased lung expression of the
PR-C clearance receptor in response to hypoxia has been
emonstrated in animal models (29). This scenario can be
een in severe chronic obstructive pulmonary disease, pri-
ary pulmonary hypertension, and other causes of pulmo-
ary hypertension (28,30,31). Because of this, when evalu-
ting acutely dyspneic patients, it is important to note that
nterpretation of NP Levels in Special Situations
Table 2 Interpretation of NP Levels in Special Situations
Causes of elevated NP levels other than CHF
LV dysfunction
Previous heart failure
Advanced age
Renal dysfunction
Acute coronary syndromes
Pulmonary disease (e.g., acute respiratory distress syndrome, lung disease
with right heart failure)
Pulmonary embolism
High output states (e.g., sepsis, cirrhosis, hyperthyroidism)
Atrial fibrillation
NP levels lower than expected
Obesity
Flash pulmonary edema
Heart failure etiology upstream from LV (e.g., acute mitral regurgitation,
mitral stenosis)
Cardiac tamponade
Pericardial constriction
dapted from Maisel A. B-type natriuretic peptide measurements in diagnosing congestive heart
ailure in the dyspneic emergency department patient. Rev Cardiovasc Med 2002;3 Suppl 4:S10–7.
CHF  congestive heart failure; LV  left ventricle; NP  natriuretic peptide.
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Natriuretic Peptides December 18/25, 2007:2357–68levated NP levels are not pathognomonic for CHF, and
ther potentially life-threatening etiologies including pul-
onary embolism must still be excluded, especially when
P levels fall within the “gray zone” (BNP 100 to 500
g/ml; NTproBNP 300 to 900 pg/ml for 50- to 75-year-
lds) (32,33).
IGH-OUTPUT STATES. Several conditions that cause high
ardiac outputs, including sepsis, cirrhosis, and hyperthy-
oidism, can contribute to elevated NP levels. Although the
echanisms are unclear, patients with severe sepsis or shock
ight have markedly elevated NP levels (34), possibly due
o induction by endotoxin or other inflammatory mediators
35) or due to underlying myocardial dysfunction (36).
alues are higher in nonsurvivors than in survivors (37).
imilarly, hyperthyroid patients might have higher NP
evels than euthyroid patients, and although the levels
ypically do not exceed diagnostic thresholds, they do tend
o decrease with treatment of the hyperthyroid state (38).
levated NP levels are also seen in patients with cirrhosis
nd likely reflect cardiac dysfunction or a hyperdynamic
irculatory state (39).
TRIAL FIBRILLATION (AF). Natriuretic peptide levels seem
o rise in the setting of AF, including lone AF (40).
owever, in an analysis of the Breathing Not Properly
tudy, Knudsen et al. (41) showed that this pattern was
resent in patients without but not with HF and that BNP
till performed well in patients with AF, with an AUC of
.84, which was only slightly lower than the AUC of 0.91
or the overall cohort. In patients with AF, a cutoff of 200
g/ml resulted in a marked improvement in specificity and
ositive likelihood ratio for diagnosing HF, compared with
he conventional cutoff of 100 pg/ml, with little loss of
ensitivity.
aveats: high levels of NPs. A number of factors have
een associated with higher NP levels in addition to
entricular wall stress.
DVANCED AGE. Both BNP and NTproBNP levels in-
rease with age (14,42), and the increased prevalence of
iastolic dysfunction alone does not seem to account for the
ntire increase. A study by Redfield et al. (13), which
xcluded patients with “age-related” diastolic dysfunction,
onetheless found an association between age and elevated
evels of BNP. Other possible explanations include altered
enal function, production, secretion, or metabolism. One
tudy has suggested that there is a reduction in the NPR-C
learance receptor with aging (43).
EMALE GENDER. B-type natriuretic peptide and NT-
roBNP are higher in women than in men at any age
13,14). Although the reason for the higher levels in women
s unknown, estrogen might play a role, because 1 study
howed that older women on hormone replacement therapy
ad higher BNP levels than women not on therapy (13).
owever, use of estrogen had only a minimal effect on
TproBNP levels in the same community cohort (42), and nther data suggest that an inverse relationship between free
estosterone levels and NPs and not estrogen levels might be
esponsible (44).
ENAL DISEASE. The association between NP levels and
enal function is complex. Patients with chronic renal
ysfunction tend to have higher atrial pressure, systemic
ressure, and ventricular mass, all of which could lead to
igher “true” physiologic NP levels; or, they might have
ncreased levels due to decreased renal filtration, decreased
learance by NPR-C and endopeptidases within renal tis-
ue, or decreased renal responsiveness to BNP.
Multiple studies have found that BNP levels begin to rise
t a threshold of estimated glomerular filtration rate (GFR)
f 60 ml/min/1.7 m2 (45), which is approximately the same
evel where increased rates of both systolic and diastolic HF
re seen. The NP elevations in patients with chronic renal
isease might reflect concurrent LV hypertrophy or coro-
ary disease (46). Because the majority of BNP is not renally
leared, the mechanism of elevated BNP levels in renal
ailure is likely multifactorial, representing in part a true
ounter-regulatory response from the heart to the kidney,
nd not simply decreased passive renal clearance. The
reathing Not Properly study found a weak but significant
orrelation between GFR and BNP and suggested that
igher cut-points are reasonable for those with GFR 60
l/min/1.7 m2 (47).
Clearance of NTproBNP, which is not mediated by the
PR-C receptor or neutral endopeptidase, might be more
ensitive than BNP to reduced renal filtration and clearance
48). In a study of breathless patients, there was a stronger
elationship between GFR and NTproBNP levels (r0.55)
han BNP levels, although the relationship was somewhat
ttenuated among patients with acute CHF (r  0.33 for
TproBNP and r  0.18 for BNP) (49). Because of this
enal influence, interpretation of NTproBNP levels might be
ore difficult in patients with a GFR 60 ml/min/1.7 m2
50,51). However, an analysis from the PRIDE study
howed that NTproBNP levels in patients with GFR 60
l/min/1.7 m2 were still the strongest independent predic-
or of outcome and suggested the higher cut-point of
TproBNP 1,200 pg/ml for diagnosing HF in such
atients (49). In relatively healthy subjects with only mild
enal impairment, in contrast, there seems to be no signif-
cant relationship between NTproBNP levels and GFR
42). Thus, NTproBNP might have additional as yet
ndiscovered modes of clearance, such as degradation by
onspecific peptidases.
Although neither BNP nor NTproBNP are cleared by
emodialysis, BNP levels do rise along with volume status
n the days leading up to hemodialysis and then drop by
pproximately 15% to 30% after a routine hemodialysis
ession (52).
aveats: low levels of NPs. OBESITY. Several studies have
ocumented lower BNP levels in obese compared with
onobese patients (14,53–55). This inverse relationship
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December 18/25, 2007:2357–68 Natriuretic Peptidesetween BMI and BNP has been observed in patients both
ith and without HF. Although the reason for the relation-
hip is unknown, the increased concentration of the NPR-C
learance receptor on adipocyte cells has led some to
ostulate that increased clearance is the reason for lower
NP levels in obese patients (56). However, evidence
gainst this hypothesis comes from Das et al. (57), who
ound that BNP was correlated with greater lean mass but
ot greater fat mass.
Whether a similar negative correlation is seen with
TproBNP is controversial; some have found that NT-
roBNP levels might be lower in obese patients, despite the
act that NTproBNP is not believed to be cleared by
PR-C (57,58). Others, however, have found that the
egree of impact of body mass index on NTproBNP was
inimal (42). A recent study of post-bariatric surgery
atients hypothesized that, because both BNP and NT-
roBNP levels increased after weight loss, decreased NP
roduction and not increased clearance might be the re-
ponsible mechanism (59).
Despite the lower circulating levels, NPs retain their
rognostic capacity in obese patients (60), although lower
P cut-points are needed for diagnosing HF in patients
ith a high body mass index (Fig. 2) (55).
LASH PULMONARY EDEMA. Natriuretic peptide levels
ight seem discordantly low in patients presenting early
ith HF symptoms that developed precipitously, in under
pproximately 1 h. In this setting, BNP gene expression has
ad insufficient time, between the initial trigger of increased
entricular wall stress and the measurement of NP levels, to
p-regulate peptide production. Because only small amounts
f BNP are stored in secretory granules, the development of
levated NP levels in flash pulmonary edema is dependent
pon the de novo synthesis and secretion of the peptide (3).
Figure 2 BNP Cut-Points for 90% Sensitivity
B-type natriuretic peptide (BNP) cut-points for 90% sensitivity in diagnosing con-
gestive heart failure in patients with dyspnea, on the basis of body mass index
(BMI) subgroup. Specificity at the 90% sensitivity level shown was at least 70%
for all 3 groups. Data from the Breathing Not Properly Multinational Study; fig-
ure adapted from Daniels et al. (55).tHFDUE TO CAUSES UPSTREAM FROMTHE LV. When CHF
s due to a cause upstream from the LV—as in acute mitral
egurgitation or mitral stenosis, for example—NP levels
ight be relatively low despite impressive symptoms. The
bsence of significant LV wall stress in these acute settings
xplains the lack of marked BNP production, and although
P levels might still be higher than normal, they will not
ise to the same degree as when the CHF occurs with a
oncomitant overload on the LV. Similarly, pericardial
onstriction can sometimes cause symptoms of CHF;
owever, because the myocardium is prevented from
tretching by the confines of the pericardium, NP levels
re typically normal or only minimally elevated in this
etting (61).
rognosis
vidence continues to mount showing that NP levels
easured in various settings are highly predictive of subse-
uent cardiac events (Table 3) (62–70).
HF. Several studies have shown that NP levels in patients
resenting with HF are predictive of future outcomes. In
oth acute and chronic HF, BNP provides important
rognostic information, with every 100-pg/ml increase as-
ociated with a 35% increase in the risk of death (71). The
rospective, multicenter REDHOT (Rapid ED Heart Fail-
re Outpatient Trial) of 464 patients presenting to the ED
ith HF showed that BNP provides prognostic value in the
cute ED setting (72). B-type natriuretic peptide was
redictive of future HF events and mortality and outper-
ormed ED physician assessment, which had poor predic-
ive value.
In chronic HF patients too, NP levels provide powerful
rognostic information about survival and are predictors of
unctional status deterioration (73,74). In an evaluation of
al-HeFT (Valsartan Heart Failure Trial) comprising
,300 outpatients with chronic HF, those with the greatest
ncrease in BNP despite therapy had the highest morbidity
nd mortality (74).
oronary artery disease (CAD)/acute coronary syndrome/
udden cardiac death. STABLE ANGINA. Both BNP and
TproBNP have strong prognostic value in patients with
table CAD and display nearly identical test performance in
redicting all-cause mortality or HF (75). In a study of
,085 patients with stable CAD followed for an average of
.5 years, BNP and LV ejection fraction were the strongest
redictors of future cardiovascular events, independent of
nown risk factors. B-type natriuretic peptide had the
ighest prognostic accuracy and was complementary to the
ngiographically defined extent of CAD and to LV systolic
unction (76). Similar prognostic utility has been demon-
trated for NTproBNP, which improved prediction of
ll-cause mortality above and beyond the predictive ability
rom conventional cardiovascular risk factors (77,78).
NSTABLE ANGINA AND MI. Natriuretic peptide levels ob-
ained in patients with unstable angina and MI also play a
Summary of Selected Studies Evaluating Prognostic Abilities of Natriuretic Peptides
Table 3 Summary of Selected Studies Evaluating Prognostic Abilities of Natriuretic Peptides
Condition Study Population n Cutoff Value End Points Change in Risk Follow-Up Ref. #
HF Meta-analysis of 4 HF studies 652 Every 100-pg/ml increase in BNP All-cause mortality 35% increased RR of death 1.4 to 2 yrs 62
Admitted with HF, REDHOT study 317 BNP 200 pg/ml All-cause mortality, CHF visit
or admission
9%, 90-day event rate (CHF visit/
admission, all-cause death)
versus 29%
63
Admitted with HF, ADHERE study 48,629 BNP 4th quartile (1,730 pg/ml)
versus 1st quartile
(430 pg/ml)
In-hospital mortality Adjusted odds ratio for mortality 2.2 In-hospital 112
ED with dyspnea, pooled analysis of 4 studies, ICON 1,256 NTproBNP 5,180 pg/ml All-cause mortality RR 5.2 for in-hospital mortality 76 days 113
Chronic HF, COPERNICUS study 1,011 NTproBNP  versus  median
(1,767 pg/ml)
All-cause mortality RR 2.7 for all-cause mortality Up to 29 months 114
Stable CAD Stable coronary heart disease, Heart and Soul Study 987 1 SD increase in logNT-proBNP;
NTproBNP 100 pg/ml
All-cause death or
hospitalization for MI, HF,
or stroke
2.3 increased risk of adverse
cardiovascular outcome; 3
increased risk above cutoff level
Mean 3.7 yrs 69
Stable CAD, AtheroGene Study 1,085 BNP 100 pg/ml MI and cardiovascular death 4.4 increased risk 2.5 yrs 67
ACS ACS, TIMI 16 study 2,525 BNP 80 pg/ml All-cause mortality Increased risk OR 5.8 for 4th
(138 pg/ml) versus 1st
(44 pg/ml) quartile
10 months 70
ACS, BNP measured at entry and 4 and 12 months;
A to Z trial
4,487 BNP 80 pg/ml Death or new-onset HF 2.5 increased risk: 3.9 at
4 months, 4.7 at 12 months
1 yr 115
SCD Ejection fraction 35% 452 BNP 130 pg/ml SCD SCD in 19% of patients above cutoff
versus 1% below cutoff
Mean 1.6 yrs 64
CRT NYHA functional class III/IV HF, undergoing CRT;
retrospective
154 BNP 447 pg/ml CRT response (No HF
hospitalization and
1 NYHA functional
class improvement)
62% sensitive, 79% specific in
identifying CRT response at
6 months (no HF hospitalization
and 1 NYHA functional class
improvement)
6 months 77
Cardiac and vascular
surgery
Male veterans undergoing open-heart surgery 98 BNP 385 pg/ml All-cause mortality and post-
operative complications
Increased risk: 90% specific,
93% NPV
1 yr 87
Major vascular surgery 335 NTproBNP 319 pg/ml All-cause mortality HR 4.0 for all-cause mortality
(10.9 for MACE)
Mean 1.2 yrs 88
PE Acute PE, consecutive 73 BNP 90 pg/ml; NTproBNP
500 pg/ml
MACE OR 8.0 for BNP, 14.6 for NTproBNP;
BNP 50 pg/ml, NTproBNP
500 pg/ml predictive of benign
clinical course
In-hospital 27,90
Pulmonary hypertension Primary pulmonary hypertension 60 BNP 180 pg/ml All-cause mortality Increased risk Mean 2 yrs 31
Pulmonary hypertension (35 idiopathic), consecutive 55 NTproBNP 1,400 pg/ml All-cause mortality 5.5 increased risk of death:
91% NPV for death if  cutoff
Mean 2.1 yrs 116
Renal dysfunction End-stage renal disease on dialysis, without HF 246 BNP tertiles: 3rd (125 pg/ml)
versus 1st (49 pg/ml)
All-cause mortality RR 7.1 Mean 2.2 yrs 117
Atrial fibrillation NYHA functional class III/IV HF (76 with atrial
fibrillation)
354 NTproBNP 449 pg/ml Cardiovascular mortality HR 5.8 in multivariate model
(HR 10.3 univariate)
Mean 3.2 yrs 118
Stroke Acute ischemic stroke 250 NTproBNP 615 pg/ml on day 2 All-cause mortality Increased risk 6 months 119
Septic shock Prospective case series study: 22 with shock, 11 with
severe sepsis, 20 healthy control subjects
53 BNP 650 pg/ml on day 2 All-cause mortality Increased risk, 92% sensitivity 1 month 120
ACS  acute coronary syndrome; ADHERE  Acutely Decompensated Heart Failure National Registry; A to Z  Aggrastat to Zocor; CAD  coronary artery disease; COPERNICUS  Carvedilol Prospective Randomized Cumulative Survival; CRT  cardiac resynchronization therapy;
ED emergency department; HF heart failure; HR hazard ratio; ICD implantable cardioverter-defibrilator; MACEmajor adverse cardiac event; NPV negative predictive value; NYHA New York Heart Association; PE pulmonary embolism; REDHOT Rapid Emergency
Department Heart Failure Outpatient Trial; RR  relative risk; SCD  sudden cardiac death; TIMI  Thrombolysis In Myocardial Infarction; other abbreviations as in Tables 1 and 2.
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December 18/25, 2007:2357–68 Natriuretic Peptidesrognostic role, which is incremental and in some instances
uperior to the prognostic value of troponins (79–82).
ersistent elevation of NTproBNP 3 to 6 months after an
cute coronary syndrome is associated with chronically
mpaired LV function (80). Some have recommended, on
he basis of these data, careful re-evaluation for risk-
educing interventions when NP levels remain elevated 3
onths after an acute coronary syndrome (83).
UDDEN CARDIAC DEATH. Several studies have shown that
Ps might be useful in predicting who is at risk for sudden
ardiac death (73,84). In 452 ambulatory patients with HF
nd LV ejection fraction 35%, BNP levels independently
redicted sudden cardiac death (73). In this study, only 1%
f patients with BNP130 pg/ml died suddenly, compared
ith 19% of patients with BNP 130 pg/ml. Natriuretic
eptides might help predict sudden cardiac death after acute
I as well. A study of 521 acute MI patients found that
NP predicted sudden cardiac death (but not other deaths)
nd was the strongest predictor even after adjusting for
linical variables, including ejection fraction (84).
In cardiomyopathy patients undergoing cardioverter-
efibrillator implantation, a single pre-implantation BNP
evel is independently predictive of future appropriate defi-
rillator therapies (85). Although decisions to implant a
efibrillator should not be made solely on the basis of NP
evels, future research might find that NP levels can help
uide our choices more wisely.
ARDIAC RESYNCHRONIZATION THERAPY. In patients with
ew York Heart Association (NYHA) functional class III
r IV HF, BNP 447 pg/ml can help predict cardiac
esynchronization therapy response at 6 months, defined as
bsence of hospital stays for HF and improvement by at
east 1 NYHA functional class (86). Cardiac resynchroni-
ation therapy induces an early and sustained reduction in
P levels, which might reflect the efficacy of the therapy
87). Future large studies will determine whether NP
evels are helpful in targeting candidates for cardiac
esynchronization and for monitoring those already with
he devices.
alvular disease. In the setting of cardiac valvular disor-
ers, NPs are becoming a useful clinical tool for monitoring
atients’ pre- and post-valvular surgery. In general, NP
evels tend to rise with increasing severity of the valvular
bnormality and with the resulting cardiac remodeling.
atriuretic peptide levels can also provide important prog-
ostic information and might assist with risk stratification
nd timing for surgery.
ITRAL VALVE. Natriuretic peptide levels increase with
ncreasing severity of mitral regurgitation (88). Recently,
NP was shown to be a marker of poor outcome in a study
f 124 patients with organic mitral regurgitation, where
evels were independently predictive of death (89).
Owing to underfilling of the LV, NP levels might not rise
s high in mitral stenosis as they might in other causes of oF; however, NP levels do increase in this setting and
ecrease after balloon valvotomy (90). Natriuretic peptide
evels are correlated with echocardiographic findings, in-
luding mitral valve area and mean mitral gradient, as well
s NYHA functional class (91).
ORTIC VALVE. In the setting of aortic stenosis, NP levels
re associated with severity of stenosis, might predict
evelopment of symptom onset, and increase progressively
ith worsening NYHA functional class (92). Levels might
lso predict survival in patients with stenosis who are treated
ithout surgery (93). In patients who do undergo valve
eplacement, NP levels might predict survival and post-
perative LV function (94).
In chronic aortic regurgitation, NP levels are also associ-
ted with severity of regurgitation even in asymptomatic
ndividuals (95), although levels tend to rise less than in
ortic stenosis even when LV dilation has occurred. Thus,
easurement of NP levels might complement clinical and
chocardiographic evaluation, particularly when symptoms
re unclear or when valvular function is difficult to interpret
n echocardiography.
ardiac and vascular surgery. Natriuretic peptide levels
easured pre-operatively can help predict post-operative
utcomes such as mortality and major adverse cardiac events
mong patients undergoing cardiac or vascular surgery
96,97). Levels can also help predict which patients are at
ncreased risk of developing post-operative AF (98).
ulmonary embolism. Patients with pulmonary embolism
nd other pulmonary diseases can also have elevated levels of
Ps, although not usually to the same extent as in CHF.
n the setting of acute pulmonary embolism, BNP levels
50 pg/ml or NTproBNP levels 500 pg/ml might help
redict a benign outcome (27,99), although some have
uggested lower cut-points for improved negative predic-
ive values.
onitoring Therapy
ecause NP levels fluctuate with changes in myocardial
lling pressures, monitoring levels might be helpful in
valuating the progress of patients receiving therapies aimed
t reducing this wall stress.
iologic variability of NP levels. Several studies have
hown considerable intraindividual variation of NP levels in
oth normal individuals and in apparently stable HF pa-
ients (100,101). These studies suggest that serial BNP
evels need to change by a minimum of approximately 70%
o constitute a significant change over 1 week in stable HF
atients and NTproBNP levels must change by at least 50%
100,101). The degree of biologic variability in acutely
ecompensated patients is more difficult to ascertain, but in
eneral, because clinical improvement should be associated
ith large changes in NP levels, the degree of intraindi-
idual variability might be less important than in the
utpatient arena of stable patients.
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Natriuretic Peptides December 18/25, 2007:2357–68npatients. Several studies have evaluated the relationship
etween NP levels and pulmonary capillary wedge pressure
easurements derived from invasive hemodynamic cathe-
ers. Not all patients with elevated NP levels will have high
edge pressures; as detailed earlier, there are many clinical
ituations in which NP levels can seem discordant with the
linical picture. Thus, in a given patient, the NP level does
ot always correlate to wedge pressure (102). However, in
atients with decompensated HF due to volume overload, a
reatment-induced drop in wedge pressure will almost
lways be accompanied by a rapid drop in NP levels,
specially during the first 24 h of treatment, as long as
dequate urine output is maintained (103).
In patients with decompensated HF, the NP level can
ypothetically be thought of as consisting of 2 components:
he “dry weight” component, which reflects the patient’s
ompensated NP level, plus the additional NP level due to
he acute pressure or volume overload.
Natriuretic peptide levels do not need to be measured
ach hospital day; however, the failure of NP levels to
ecrease during hospital stay is a poor prognostic sign
104,105). More important than repeated measurements of
P levels in inpatients is obtaining a level immediately
efore discharge. A single pre-discharge BNP level is
trongly predictive of early and later outcome, regardless of
he initial BNP level or echocardiographic findings (106). In
study of 114 patients admitted with CHF, those with a
re-discharge BNP level 700 pg/ml were over 15 times
ore likely to die or get readmitted within 6 months
ompared with those with BNP 350 pg/ml at discharge
107).
A reasonable approach to monitoring inpatients with
ecompensated HF would be to obtain an NP level on
dmission and just before discharge when the patient is
resumed to be euvolemic, both for prognostic purposes and
o aid in tailoring the intensity of post-discharge care (108);
t might also help to establish the patient’s “dry weight” NP
evel, although patients often need additional diuresis after
ischarge, leading ultimately to a dry weight NP level lower
han the discharge level. Additional measurement of NP
evels in inpatients might be appropriate if the patient
xperiences a significant change in status during the hospital
tay, although the benefit of this has not been tested.
utpatients. Monitoring NP levels in the outpatient set-
ing might improve patient care and outcomes, although
rospective studies of this have shown conflicting results. In
he STARS-BNP (Systolic Heart Failure Treatment Sup-
orted by BNP) study of 220 patients with HF and LV
ysfunction who were randomized to receive therapy guided
y NP levels or standard care, NP-guided treatment target-
ng a BNP level 100 pg/ml significantly reduced HF
eaths and hospital stays for HF (109). However, the
maller STARBRITE (Strategies for Tailoring Advanced
eart Failure Regimens in the Outpatient Setting: BRain
atrIuretic Peptide Versus the Clinical CongesTion ScorE)tudy (n  130) failed to show a significant improvement in mhe primary outcome of nonhospital days alive in patients
hose treatment was guided by BNP levels, although
TARBRITE enrolled sicker patients and used a higher
NP target than STARS-BNP (110). In both STARS-
NP and STARBRITE, clinicians who adjusted treatments
ased on BNP levels prescribed higher doses of angiotensin-
onverting enzyme (ACE) inhibitors and beta blockers,
ompared with those whose treatment was guided by
linical signs and symptoms alone.
For patients regularly followed in clinic, it might be
eneficial to establish their “steady state” NP level, that is,
he BNP or NTproBNP level that corresponds to their
ptimized fluid status. Knowing a patient’s steady state NP
evel might be helpful for management in both the inpatient
nd outpatient settings, because baseline NP levels can vary
n the basis of the patient’s underlying severity of disease
nd NYHA functional class (111). Significant deviations
bove this steady state value might prove more helpful than
raditional cut-points for diagnosing HF exacerbations in
hose individuals who are closely followed as outpatients and
hose NP levels tend to stay elevated, whereas values much
ower than their steady state level might signal a patient who
s over-diuresed or intravascularly depleted.
A post-discharge rise in NP level can be an important
arker for repeat hospital stay. How high an NP level must
ise over baseline before a patient is deemed “decompen-
ated” is unknown, because as noted previously, there is a
ertain amount of intraindividual variation in NP levels, and
ertainly the clinical picture is important in this regard.
owever, an increase by at least 50% over one’s steady state
P level might be a reasonable benchmark for triggering an
valuation for confirmatory signs and symptoms followed by
ore aggressive treatment.
oward the Future—
creening for Subclinical Disease
p to one-half of individuals with LV dysfunction might be
symptomatic and unaware of their condition (112,113).
ecause NPs are elevated in the setting of LV dysfunction,
heir use as a screening test for this condition has aroused
uch interest. Although echocardiography is the current
old standard for detection of LV dysfunction and many
ther structural cardiac abnormalities, its cost and limited
vailability make it an impractical choice for mass screening.
Several studies have evaluated the use of NPs to identify
symptomatic subjects with poor ventricular function. Most
oncluded that, owing to the relatively low prevalence of
isease, the best potential use for NPs was to use the high
egative predictive value for “ruling out” disease (114,115).
ther studies looking to screen for a broader range of
ubclinical cardiovascular disorders also found excellent
egative predictive value (116).
The diagnostic value of NPs in community screening
epends largely on the prevalence of disease. As such, NPs
ight be most useful for detecting a range of clinical
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December 18/25, 2007:2357–68 Natriuretic Peptidesisorders. In the Framingham Offspring Study of 3,346
symptomatic middle-age subjects, for example, Wang et al.
117) prospectively examined BNP and NT-proANP levels
nd found that BNP levels were independently predictive of
he risk of death, HF, stroke or transient ischemic attack,
nd AF, even after adjusting for traditional risk factors. The
NP levels above the 80th percentile (approximately 20
g/ml) carried a 62% increased risk of death and a 76%
ncreased risk of a first major cardiovascular event. With
ach increment of 1 SD in log BNP levels, there was a 27%
ncrease in risk of death, a 77% increase in risk of HF, a 66%
ncrease in the risk of AF, and a 53% increase in the risk of
troke or transient ischemic attack, all of which were
tatistically significant. Another study in nonhospitalized
ndividuals ages 50 to 89 years showed that NTproBNP
rovides prognostic information of mortality and first major
ardiovascular events beyond traditional risk factors (118).
hus even small elevations of NP levels (e.g., in the BNP
0- to 100-pg/ml range), significantly less than traditional
ut-points for acutely dyspneic patients, might serve as an
arly warning sign, aiding in the timely detection of cardio-
ascular disease.
An intriguing future use of NPs might be as an adjunct to
he athletic pre-participation screening exam. A preliminary
tudy of college athletes showed that most have low levels of
Ps (15); on the basis of what is known about NPs, athletes
ith the highest NP levels might have a physiologic basis
or the elevation and might represent a higher-risk subgroup
hat warrants closer evaluation. However, large-scale studies
re needed to evaluate the incremental value and cost-
ffectiveness of using NPs in this setting.
ost-effectiveness. Screening populations at high risk for
evelopment of HF, such as diabetic and elderly patients,
nd referring those with elevated NP levels for echocardio-
ram might in fact prove cost-effective despite the higher
revalence of elevated NP levels in these populations
119,120). Heidenreich et al. (120) recently found that
sing a BNP cutoff level of 24 pg/ml for echocardiogram
eferral was a cost-effective means of screening for LV
ysfunction in populations (such as men over age 60 years
nd possibly women over age 60 years) with a prevalence of
V systolic dysfunction of at least 1%.
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